U.S. Pharma Stock News

NYSE:BXMT
NYSE:BXMTMortgage REITs

A Look At Blackstone Mortgage Trust (BXMT) Valuation After Recent Share Price Weakness

What Just Happened With Blackstone Mortgage Trust? Blackstone Mortgage Trust (BXMT) has been drawing attention after a recent stretch of weak share performance, with the stock showing negative returns over the past week, month, past 3 months, and year to date. For investors watching income oriented real estate finance names, this mixed picture, including positive 1 year and 3 year total returns alongside a 5 year total return decline, raises questions about how current fundamentals and...
NYSE:BRBR
NYSE:BRBRPersonal Products

Will Stockpiling Lawsuits Overstate BellRing Brands' (BRBR) Growth Story And Shift Its Investment Narrative?

In the past few months, BellRing Brands and several senior executives have been hit with multiple securities class action lawsuits alleging that earlier sales growth was artificially boosted by retailer inventory stockpiling rather than genuine consumer demand, and that competitive pressures and inventory adjustments were not fully disclosed to investors. These cases focus on whether management’s communications gave an accurate picture of underlying demand and retailer behavior, raising...
NYSE:FOA
NYSE:FOADiversified Financial

Finance Of America Companies (FOA) Earnings Surge Tests Long Term Decline Narrative

Finance of America Companies (FOA) just closed out FY 2025 with fourth quarter revenue of US$73.5 million and a basic EPS loss of US$1.26, following a year in which trailing twelve month EPS reached US$5.41 on revenue of US$497.4 million. The company has seen quarterly revenue move from US$290.1 million in Q3 2024 to US$73.5 million in Q4 2025, while basic EPS shifted from a profit of US$8.48 to a loss of US$1.26 over the same period. This sets up a mixed picture that investors will read...
NasdaqGM:ORKA
NasdaqGM:ORKABiotechs

Assessing Oruka Therapeutics (ORKA) Valuation As ORKA-001 Moves Into Long Term Psoriasis Trial

Oruka Therapeutics (ORKA) has begun an open-label extension Phase 2 trial of ORKA-001 in moderate to severe plaque psoriasis, evaluating long term safety, efficacy, and potentially convenient once yearly dosing schedules. See our latest analysis for Oruka Therapeutics. The latest ORKA-001 trial update comes after a strong run in the stock, with a year to date share price return of 19.17% and a 1 year total shareholder return above 200%. This suggests momentum has been building as investors...
NYSEAM:CMT
NYSEAM:CMTChemicals

Core Molding Technologies (CMT) Margin Dip To 4.1% Tests Bullish Expansion Narrative

Core Molding Technologies (CMT) has wrapped up FY 2025 with fourth quarter revenue of US$74.7 million and basic EPS of US$0.36 on net income of US$3.1 million, with the trailing twelve month figures sitting at US$273.8 million of revenue and EPS of US$1.31. Over recent periods the company has seen quarterly revenue range from US$58.4 million to US$79.2 million, with basic EPS moving between US$0.22 and US$0.47. This gives investors a clear view of how earnings power has tracked alongside the...
NYSE:LDI
NYSE:LDIDiversified Financial

LoanDepot (LDI) Q4 Loss Widens Versus Q3 And Tests Bullish Profitability Narratives

loanDepot (LDI) just wrapped up FY 2025 with Q4 revenue of US$266.6 million and a net loss of US$22.5 million, which translated to EPS of a US$0.10 loss, setting a cautious tone for the full year. The company has seen quarterly revenue move from US$164.9 million in Q4 2024 to US$266.6 million in Q4 2025, while EPS shifted from a US$0.17 loss to a US$0.10 loss over the same stretch, leaving investors focused on how much of that top line is making it through to the bottom line. The latest...
NasdaqGS:DAKT
NasdaqGS:DAKTElectronic

Should Daktronics’ (DAKT) Profit Return and Completed Buyback Prompt a Fresh Look From Investors?

Daktronics, Inc. has completed a long-running share repurchase program and reported improved past-quarter results, with sales rising to US$181.87 million and net income of US$3.01 million versus a loss a year earlier. Alongside this return to profitability, a US$25 million OCVIBE partnership and the retirement of 11.46% of its shares highlight how Daktronics is pairing large-scale project wins with capital returns. Next, we’ll examine how Daktronics’ swing back to profitability and...
NasdaqCM:EVLV
NasdaqCM:EVLVElectronic

Evolv Technologies Holdings (EVLV) Q4 Profit Tests Narratives Around Persistent Annual Losses

Evolv Technologies Holdings (EVLV) just wrapped up FY 2025 with Q4 revenue of US$38.5 million and basic EPS of US$0.06, alongside trailing twelve month revenue of US$145.9 million and a basic EPS loss of US$0.20. The company has seen quarterly revenue move from US$29.1 million in Q4 2024 to US$38.5 million in Q4 2025, while basic EPS shifted from a loss of US$0.10 to EPS of US$0.06 over the same period. This has set up a results season where investors are weighing solid top line progress...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

Assessing Popular (BPOP) Valuation After Recent Share Price Weakness And Long Term Gains

Popular’s recent share performance and financial profile Popular (BPOP) has attracted attention after a mixed stretch in its share performance, including a 0.8% decline over the past day, a 5.2% decline over the past week, and a 12.5% decline over the past month. In contrast to that shorter term weakness, the bank shows a 6.6% gain over the past 3 months, with total returns of 2.3% year to date and 51.9% over the past year, along with very large 3 year and 5 year total returns. At a last...
NYSE:SWK
NYSE:SWKMachinery

Is Stanley Black & Decker (SWK) Pricing Reflecting Its Recent Multi‑Year Share Price Weakness

If you are wondering whether Stanley Black & Decker is attractively priced today, the key question is whether the current share price fairly reflects the company’s underlying fundamentals. The stock closed at US$73.74, with returns of 7.6% decline over 7 days, 17.9% decline over 30 days, a 3.6% decline year to date, a 4.8% decline over 1 year, a 4.2% return over 3 years and a 55.1% decline over 5 years. This performance may have some investors reassessing both risk and potential...
NasdaqGS:OTTR
NasdaqGS:OTTRElectric Utilities

Otter Tail (OTTR) Valuation Check After Rate Settlement Approval And Earnings Slowdown Forecast

The South Dakota Public Utilities Commission’s approval of Otter Tail (OTTR) subsidiary Otter Tail Power’s rate settlement, which includes a moratorium on further base rate hikes until late 2029, gives investors a clearer view of future regulated revenue. See our latest analysis for Otter Tail. Against this regulatory backdrop, Otter Tail’s share price has eased in the very short term, with a 7 day share price return of 3.89% and a 30 day share price return of 0.54%. However, its 1 year total...
NasdaqGS:PTEN
NasdaqGS:PTENEnergy Services

Does Patterson-UTI (PTEN) Insider Selling Undercut The Dividend-Higher Free Cash Flow Narrative?

Goldman Sachs recently reaffirmed its positive stance on Patterson-UTI Energy, highlighting resilient customer activity despite Middle East geopolitical risks, strong adjusted free cash flow in FY 2025, and a 25% increase in the quarterly dividend implemented in early 2026. At the same time, Director Tiffany Cepak’s sale of 12,000 shares, leaving her with 161,111 shares amid a pattern of more insider sells than buys over the past year, offers an additional data point on insider behavior for...
NYSE:VTOL
NYSE:VTOLEnergy Services

Bristow Group Tests Autonomous Cargo To Reshape Energy Logistics Outlook

Bristow Group (NYSE:VTOL) joined the U.S. Department of Transportation’s eVTOL Integration Pilot Program. The company is partnering with Elroy Air to deploy the Chaparral autonomous cargo drone. The program targets aerial cargo delivery opportunities for the energy sector along the U.S. Gulf Coast. Bristow Group, best known for crew transport and search and rescue services, is now stepping into autonomous aerial cargo through its work with Elroy Air. By participating in the U.S. Department...
NasdaqGM:IRON
NasdaqGM:IRONBiotechs

Is Disc Medicine (IRON) Pricing Attractive After Recent Pullback And DCF Valuation Gap

If you are trying to work out whether Disc Medicine is attractively priced today, it helps to first look at how the market has been treating the stock and what that might imply about expectations. The share price recently closed at US$66.18, with returns of 2.8% over the last 7 days, a 17.0% decline over 30 days, a 16.3% decline year to date, and a 22.8% gain over the past year. Taken together, this gives you a mixed picture of sentiment and risk. Recent news coverage around Disc Medicine...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

eToro Buyback Shrinks Share Count And Reshapes Future Capital Returns

eToro Group (NasdaqGS:ETOR) has completed a significant share buyback tranche. The company repurchased nearly 4% of its shares outstanding. This buyback represents a material capital allocation move for existing and prospective shareholders. eToro Group runs a multi asset investment platform that gives users access to equities, cryptoassets and other instruments. This position places the company at the intersection of retail trading and digital finance. As regulators around the world keep a...
NYSE:SUNB
NYSE:SUNBTrade Distributors

How Sunbelt’s U.S. Redomiciliation and NYSE Move At Sunbelt Rentals Holdings (SUNB) Has Changed Its Investment Story

In early March 2026, Ashtead Group completed its U.S. redomiciliation, rebranded as Sunbelt Rentals Holdings, shifted its primary listing from the London Stock Exchange to the New York Stock Exchange, and replaced PwC UK with PwC US as its independent auditor for the fiscal year ending April 30, 2026. The move aligns the listed entity, governance structure and audit oversight with Sunbelt Rentals’ largely North American operations, potentially improving investor familiarity and access to...
NasdaqGS:KALU
NasdaqGS:KALUMetals and Mining

Kaiser Aluminum (KALU) Valuation Check After Fund Spotlight And Capacity Expansion Progress

Third Avenue Small-Cap Value Fund recently put Kaiser Aluminum (KALU) in the spotlight after reporting quarterly financial results and progress on a multi year capacity expansion in aerospace and packaging. See our latest analysis for Kaiser Aluminum. At a share price of US$125.09, Kaiser Aluminum has seen a 90 day share price return of 17.53% and a year long total shareholder return of 91.11%. This suggests recent momentum following the fund's positive commentary and capacity expansion...
NasdaqGM:ENPH
NasdaqGM:ENPHSemiconductor

Is It Time To Reassess Enphase Energy (ENPH) After Sharp Multi‑Year Share Price Swings

If you are trying to figure out whether Enphase Energy is attractively priced today, an important question is whether the current share price reflects what the business is really worth. The stock last closed at US$43.59, with returns of 0.9% over 7 days, a 12.5% decline over 30 days, a 29.2% gain year to date, a 28.3% decline over 1 year, and a 79.5% decline over 3 years, which gives a mixed picture of recent and medium term sentiment. Recent moves in solar and clean energy names have kept...
NYSE:JOE
NYSE:JOEReal Estate

A Look At St. Joe (JOE) Valuation After Strong 1 Year Returns And DCF Implied Upside

St. Joe (JOE) has drawn investor attention after recent share price moves, with the stock showing mixed short term performance alongside relatively stronger results over the past year and the past three months. See our latest analysis for St. Joe. At a share price of US$70.59, St. Joe has seen short term share price weakness over the past week, alongside stronger momentum over the past three months and solid 1 year total shareholder returns of 61.27%. If St. Joe’s move has you thinking about...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

Legend Biotech (LEGN) Q4 Loss Narrows To US$30.9m Testing Bullish Profitability Narrative

Legend Biotech (LEGN) has wrapped up FY 2025 with fourth quarter revenue of US$306.3 million and a basic EPS loss of US$0.17, alongside net income excluding extra items showing a loss of US$30.9 million. Trailing twelve month revenue reached about US$1.0 billion and EPS on this basis was a loss of US$1.61. The company has seen quarterly revenue move from US$186.5 million in Q4 2024 to US$306.3 million in Q4 2025, with quarterly basic EPS shifting from a profit of US$0.14 to a loss of US$0.17...
NasdaqGS:STEP
NasdaqGS:STEPCapital Markets

StepStone Expands Leadership And Backs US$1b Glade Brook Fundraise

StepStone Group (NasdaqGS:STEP) has promoted a new class of 11 partners alongside expanded senior and managing director roles. The firm also acted as a lead investor in Glade Brook's oversubscribed Gondola Fund, part of a US$1b capital raise. These developments reflect internal leadership expansion and active participation in private market fundraising activity. StepStone Group focuses on private markets, connecting institutional and other investors to private equity, private credit and...
NYSE:ASGN
NYSE:ASGNIT

ASGN Bets On Quinnox And Everforth Rebrand To Grow AI Platform

ASGN (NYSE:ASGN) has closed its acquisition of digital engineering firm Quinnox, expanding its global delivery footprint. The company is integrating Quinnox to strengthen offshore capabilities and support AI focused services. ASGN is realigning senior leadership, including hires from large technology and consulting firms, to oversee the combined digital engineering operations. The business is preparing to rebrand under the Everforth name, signaling a broader repositioning of its technology...
NasdaqGS:QS
NasdaqGS:QSAuto Components

Is QuantumScape (QS) Pricing Reflect Its Potential After Recent Volatility In The Share Price

If you are wondering whether QuantumScape's current share price reflects its true potential, this article will walk you through what that might mean for you as an investor. The stock recently closed at US$6.82, with a 4.3% gain over the past week, a 19.5% decline over the last 30 days, a 38.3% decline year to date, and a 60.8% return over the past year that contrasts with a 3.3% decline over three years and an 88.0% decline over five years. Recent attention around QuantumScape has continued...
NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback

If you are wondering whether Neurocrine Biosciences is attractively priced today, this article walks through what the current share price might be implying about its value. The stock most recently closed at US$129.86, with a 1 year return of 21.1% that sits alongside a 7.6% decline year to date and a 30 day return of 8.0% decline. That mix of gains over 1 year and pullback in the shorter term often prompts investors to look more closely at what the market is focusing on, including product...